HMG LEPORI

Informació principal

  • Denominació comercial:
  • HMG LEPORI 75/75 UI 10 viales + 10 ampollas 1 ml
  • formulario farmacéutico:
  • Inyectables
  • Vía de administración:
  • Intramuscular
  • Utilitza per:
  • Humans
  • Tipo de medicina:
  • medicament al·lopàtic

Documents

Localització

  • Disponible en:
  • HMG LEPORI 75/75 UI 10 viales + 10 ampollas 1 ml
    Andorra
  • Idioma:
  • català

Altres dades

Estat

  • Font:
  • CedimCat - Centre d'Informació de Medicaments de Catalunya
  • Número d'autorització:
  • 654320
  • última actualització:
  • 08-06-2018

Prospecte: composició, indicacions, interacció, posologia, embaràs, lactància, reaccions adverses

HMG LEPORI 75/75 UI 10 viales + 10 ampollas

1 ml

hormona FSH + hormona LH

Indicacions

Medicament que estimula l'ovulaci

en la dona.

Tamb

s'utilitza en el tractament de l'esterilitat funcional masculina.

Consideracions

Aquest medicament ha de ser administrat per via intramuscular.

Aquest medicament ha de ser administrat per un metge o un altre professional sanitari amb experi

ncia.

Aquest medicament

s d'un sol

s; rebutgi qualsevol resta de medicament que pugui quedar a l'env

s una vegada utilitzat.

Segueixi estrictament la pauta indicada pel seu metge pel que fa a dosi i freq

眉猫

ncia d'administraci

Avisi el seu metge si pateix o ha patit problemes de circulaci

o problemes de tiroides.

Aquest medicament pot donar un resultat positiu en els controls de dopatge.

Informi immediatament el seu metge si est

embarassada o creu que pot estar-ho, aix

com si qued

s embarassada durant el tractament.

Avisi al seu metge si t

algun fill a qui estigui alletant.

Efectes adversos

Avisi el seu metge si durant el tractament apareix dolor abdominal, augment de pes o dificultat per

respirar.

Aquest medicament pot produir envermelliment o mol

sties al punt d'aplicaci

, mal de cap i mol

sties gastrointestinals (n

usees, v

mits, etc.).

Si not

s qualsevol altre s

mptoma que creu que pot ser causat per aquest medicament, digui-li-ho al

seu metge.

Posologia

Segueixi la pauta indicada pel seu metge.

VIA INTRAMUSCULAR.

4-4-2019

FDA expands approved use of metastatic breast cancer treatment to include male patients

FDA expands approved use of metastatic breast cancer treatment to include male patients

The FDA is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.

FDA - U.S. Food and Drug Administration

12-6-2018

Dave’s Pet Food Voluntarily Recalls 95% Premium Beef Canned Dog Food Due to Potentially Elevated Levels of Thyroid Hormone

Dave’s Pet Food Voluntarily Recalls 95% Premium Beef Canned Dog Food Due to Potentially Elevated Levels of Thyroid Hormone

Dave’s Pet Food of Agawam, MA is recalling a single lot of Dave’s Dog Food 95% premium beef cans because the products potentially contain elevated levels of beef thyroid hormone.

FDA - U.S. Food and Drug Administration

29-5-2018

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal placebo capsules instead of active capsules. As a result of this packaging error, oral contraceptive capsules, that are taken out of sequence, may place the user at risk for contraceptive failure and unintended pregnancy. The reversing of the order may not be apparent to either new users or previous ...

FDA - U.S. Food and Drug Administration

29-5-2018

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians sample pack, indicated for use by women to prevent pregnancy. Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal...

FDA - U.S. Food and Drug Administration

23-5-2018

Merrick Pet Care Voluntarily Recalls Limited Amount of Good Buddy and Backcountry Treats Containing Beef Due to Potentially Elevated Levels of Thyroid Hormone

Merrick Pet Care Voluntarily Recalls Limited Amount of Good Buddy and Backcountry Treats Containing Beef Due to Potentially Elevated Levels of Thyroid Hormone

Merrick Pet Care, of Amarillo, Texas, is initiating a voluntary recall of a limited amount of beef dog treat varieties due to the potential that they contain elevated levels of a naturally-occurring beef thyroid hormone.

FDA - U.S. Food and Drug Administration

6-5-2014

Guidance material to doctors and users of contraceptive pills

Guidance material to doctors and users of contraceptive pills

The EU Pharmacovigilance Risk Assessment Committee (PRAC) recently completed a review of the risk of blood clots (VTE) with contraceptive pills and other combined hormonal contraceptives. Combined hormonal contraceptives contain two types of hormone, oestrogen and progesterone, and are available as pills, transdermal patches and vaginal rings.

Danish Medicines Agency

8-3-2019

EU/3/08/545 (Clinuvel Europe Limited)

EU/3/08/545 (Clinuvel Europe Limited)

EU/3/08/545 (Active substance: [Nle4, D-Phe7]-alpha-melanocyte stimulating hormone) - Transfer of orphan designation - Commission Decision (2019)1948 of Fri, 08 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004293

Europe -DG Health and Food Safety

8-3-2019

EU/3/08/541 (Clinuvel Europe Limited)

EU/3/08/541 (Clinuvel Europe Limited)

EU/3/08/541 (Active substance: [Nle4, D-Phe7]-alpha-melanocyte stimulating hormone) - Transfer of orphan designation - Commission Decision (2019)1947 of Fri, 08 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004019

Europe -DG Health and Food Safety

21-2-2019


Orphan designation: Recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains (somavaratan), Treatment of growth-hormone deficiency, 05/08/2013, Withdrawn

Orphan designation: Recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains (somavaratan), Treatment of growth-hormone deficiency, 05/08/2013, Withdrawn

Orphan designation: Recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains (somavaratan), Treatment of growth-hormone deficiency, 05/08/2013, Withdrawn

Europe - EMA - European Medicines Agency

17-1-2019

Natpar (Shire Pharmaceuticals Ireland Limited)

Natpar (Shire Pharmaceuticals Ireland Limited)

Natpar (Active substance: parathyroid hormone) - PSUSA - Modification - Commission Decision (2019)269 of Thu, 17 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10591/201804

Europe -DG Health and Food Safety

19-12-2018


Orphan designation: Somapacitan, Treatment of growth hormone deficiency, 24/08/2018, Positive

Orphan designation: Somapacitan, Treatment of growth hormone deficiency, 24/08/2018, Positive

Orphan designation: Somapacitan, Treatment of growth hormone deficiency, 24/08/2018, Positive

Europe - EMA - European Medicines Agency

19-12-2018

EU/3/12/1087 (Richardson Associates Regulatory Affairs Ltd)

EU/3/12/1087 (Richardson Associates Regulatory Affairs Ltd)

EU/3/12/1087 (Active substance: Recombinant modified human growth hormone) - Transfer of orphan designation - Commission Decision (2018)9014 of Wed, 19 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002652

Europe -DG Health and Food Safety